Inside Out: Regenerative Medicine for Recessive Dystrophic Epidermolysis Bullosa

Inside out: regenerative medicine for recessive dystrophic epidermolysis bullosa

Epidermolysis bullosa is classified as a genodermatosis, an inherited genetic skin disorder that results in severe, chronic skin blistering with painful and life-threatening complications. Although there is currently no cure for epidermolysis bullosa, concurrent advances in gene and stem cell therapies are converging toward combinatorial therapies that hold the promise of clinically meaningful and lifelong improvement. Recent studies using hemat…

Cell-based, gene therapy skin grafts heal large epidermolysis bullosa wounds

Genetically engineered skin grafts exhibited a long-term ability to heal large, chronic wounds in patients with recessive dystrophic epidermolysis bullosa, according to study results published in The Lancet. “Epidermolysis bullosa (EB) is a family of diseases, with dystrophic EB being one of the more severe variants,” Peter Marinkovich, MD, associate professor of dermatology at

Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa

RDEB is a lifelong debilitating, blistering skin disease associated with large and painful wounds that often remain open for years and cause significant...

Israeli Researchers Develop Skin Graft Technology That Halves Healing Time - The Media Line

Motivated by the number of burn victims from […] The post Israeli Researchers Develop Skin Graft Technology That Halves Healing Time appeared first on The Media Line.

Phase III trial shows gene therapy skin grafts help heal chronic wounds in blistering skin disease

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown. The grafts treat severe dystrophic epidermolysis bullosa, or EB, a genetic condition in which the skin is so fragile the slightest touch can cause blistering and wounds, eventually leading to large, open lesions that never heal and are immensely painfu…

New Phase 3 VIITAL Data Confirms Efficacy of Abeona’s Pz-cel for RDEB

Abeona Therapeutics' VIITAL trial reveals promising results for RDEB treatment, showcasing significant wound healing and pain relief with Zevaskyn therapy.